Jeff Jonas, Kenai Therapeutics chairman
February 29, 2024 11:05 AM ESTUpdated 05:32 PM
Financing
Startups
Cell/Gene Tx

'Sweet spot' of CNS cell ther­a­py: Ke­nai emerges with $82M for Parkin­son's study

Kyle LaHucik

Senior Reporter

One of the first drugs that Jeff Jonas filed for ap­proval was a Parkin­son’s dis­ease treat­ment. Now, a lit­tle over a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times